High Tide Inc. (HITI) Q3 2026 earnings review
Operating leverage expands despite flat core retail growth
High Tide reported Q3 revenue of $198.8 million, up 32.8% year-over-year. The headline masks a split reality: the legacy bricks-and-mortar segment grew 7.3%, while the acquired medical cannabis business added $38.2 million. Operating income reached $8.7 million, up from $3.7 million a year ago, though the $12.7 million net income headline is heavily inflated by non-cash derivative gains. The company issued no formal financial guidance in the interim filing.
⚖️ Verdict: 🟢 Bullish
The case is better — a bullish verdict — because operating leverage is expanding even as the core retail segment grows in the mid-single digits. General and administrative expenses fell in points of revenue, proving the infrastructure can support the rapidly scaling international medical business without parallel cost additions.
What the print did not settle is whether the Canadian retail footprint has bottomed organically. Management previously blamed a 1.2% same-store sales decline on temporary macro pressure; the next call's breakdown of organic versus acquisition-driven growth will settle whether that pressure has cleared.
🐂 Bull Case
Medical Cannabis Expansion Outpaces the Core
Remexian is carrying the top line. The medical cannabis distribution segment added $38.2 million in revenue, accelerating from $31.6 million last quarter and now representing nearly a fifth of total sales.
The segment operates at a 6.1% operating margin, outperforming the core retail footprint and proving the acquisition can scale without dragging down consolidated profitability.
Operating Leverage Drops to the Bottom Line
The company is absorbing its growth efficiently. General and administrative expenses fell to 3.9% of revenue from 4.4% a year ago, generating pure operating leverage.
That discipline passed directly through to the operating line, where income more than doubled to $8.7 million. Scaling the infrastructure without parallel cost additions is the cleanest positive in the print.
🐻 Bear Case
The Net Income Print is a Derivative Illusion
The headline net income figure implies a fundamentally transformed bottom line, but the cash reality is much smaller. Nearly all of the $12.7 million print rests on an $11.8 million non-cash fair-value gain tied to a put option from the Remexian acquisition.
Backing out that paper adjustment leaves clean pre-tax income at roughly $0.9 million. The core operating growth is real and impressive, but the 1,788% bottom-line growth headline is strictly an accounting mechanic.
Canadian Retail Growth Remains Constrained
The core retail business has stopped decelerating, but it is not accelerating either. Segment growth landed at 7.3%, virtually flat against Q2's 7.1% and roughly half the rate it carried a year ago.
Without same-store sales disclosures in this interim filing, the reading implies the macroeconomic pressure on the core blue-collar customer — which management flagged heavily last quarter — has not lifted.
👓 Other Themes
Transitioning the Capital Structure
The balance sheet is turning over. High Tide drew $7.3 million on a new bank facility in July, matching the timeline management laid out last quarter to replace its legacy credit lines with Tier 1 bank debt. The legacy connectFirst loan was discharged in August.
💲 Other KPIs
Flat against the prior year despite 32.8% top-line growth, demonstrating highly efficient working capital controls.
Nearly tripled from $3.6 million a year ago, driven primarily by factoring arrangements within the Remexian subsidiary.
Increased 6.8% year-over-year, slowing against historical issuance rates as the company begins to fund operations organically.
🔮 Guidance
The Q3 condensed interim financial statements do not provide an operational update on store counts. The prior goal of 20-30 new locations in calendar 2026 remains the standing target until management updates it on the call.
❓ Key Questions
Canadian Same-Store Sales
Did Canadian same-store sales remain negative in Q3, or did the 7.3% segment growth include a positive organic contribution?
Remexian Revenue Run Rate
Does the $38.2 million reading for Remexian represent a clean run rate, or were there timing effects from bulk international shipments artificially lifting the quarter?
UK Expansion Target
What is the status of the active M&A discussions in the U.K. market mentioned during last quarter's call?